A recent crackdown in Gurugram has exposed a growing risk in India’s pharmaceutical landscape.
According to Hindustan Times, authorities seized counterfeit Mounjaro injections worth ₹56 lakh and arrested two individuals. The case stands out not just for its value, but for the nature of the product. These were injectable drugs, typically used under medical supervision, now circulating in an unregulated market.
Mounjaro, developed by Eli Lilly, is used for diabetes and increasingly for weight loss. Its rising demand has made it a high-value target for counterfeit networks.
Mounjaro Demand Surge
Mounjaro belongs to a class of drugs called GLP-1 receptor agonists. These drugs have seen unprecedented global demand, especially for weight management. Reports have highlighted supply shortages of similar drugs like Ozempic and Wegovy due to demand outpacing production.
India is still an emerging market for these drugs, but urban demand is rising rapidly. High prices and limited availability create a gap that informal markets often exploit.
Black Market Growth
Counterfeit drugs do not appear randomly. They follow incentives.
In the case of Mounjaro, the incentives are unusually strong. A high-value injectable drug, limited legal supply, rising consumer demand, and low awareness create ideal conditions for a parallel market. The Gurugram case reflects exactly this combination.
Unlike traditional counterfeit medicines that target mass consumption, this is a shift towards premium counterfeiting. The consumer is not looking for the cheapest option. They are looking for access.
That distinction changes the economics. It allows counterfeiters to operate at higher margins while still appearing “credible” to buyers.
Consumers often believe they are purchasing genuine imported products, when in reality they are exposed to unknown substances.
Pattern Of Counterfeits
India has a documented history of substandard and counterfeit medicines. The Central Drugs Standard Control Organisation regularly publishes alerts on drugs that fail quality tests, categorised as “Not of Standard Quality.”
Globally, counterfeit versions of high-value drugs like Keytruda have been reported, according to Reuters. While these cases are not always India-specific, they highlight a consistent pattern. High-demand, high-cost drugs attract counterfeiters.
Reports show around 4% of tested drug samples fail quality standards, indicating a persistent systemic issue . In multiple recent cases, companies have denied responsibility, claiming products were counterfeit versions of their brands circulating in the market. These patterns show that fake and substandard drugs are not isolated incidents but recurring failures across the supply chain.
Beyond Pharmaceuticals
Counterfeiting in India extends beyond medicines. Reports have documented fake versions of everyday products such as toothpaste, packaged foods, and personal care items.
This reflects a broader counterfeit ecosystem where distribution networks operate across categories. Once established, these networks can easily expand into high-risk sectors like pharmaceuticals.
Supply Chain Gaps
The entry of counterfeit drugs into the market is often linked to weak points in the supply chain. These include unauthorised wholesalers, poor tracking systems, and fragmented distribution networks.
The World Health Organization estimates that about 1 in 10 medical products in low and middle income countries is substandard or falsified. These products often closely mimic legitimate packaging, making detection difficult for consumers.
India’s vast and decentralised pharmaceutical distribution system adds to the challenge of monitoring and enforcement.
Health Risks Involved
The risks associated with counterfeit drugs are severe, especially in the case of injectables. Unlike oral medicines, injections enter the bloodstream directly, increasing the risk of immediate adverse reactions.
Fake drugs may contain incorrect dosages, harmful chemicals, or no active ingredient. This can result in treatment failure, toxicity, infections, or long-term health damage.
Public health experts have warned that counterfeit medicines not only endanger individual patients but also erode trust in healthcare systems.
Regulatory Response India
Containing counterfeit medicines requires closing supply chain gaps before products reach consumers. Experts and regulators emphasise track-and-trace systems, stricter surveillance, and stronger coordination between state and central authorities. In a recent discussion, the National Human Rights Commission outlined key measures:
- Expanding track and trace systems for pharmaceutical supply chains
- Increasing frequency of random drug testing
- Strengthening coordination between central and state regulators
- Enhancing penalties for counterfeit drug production
- Improving consumer awareness on verifying medicines
These steps aim to shift the system from reactive crackdowns to preventive regulation.
The Logical Indian’s Perspective
The Gurugram seizure highlights a deeper issue within India’s healthcare and regulatory system. As demand for advanced medicines grows, gaps in accessibility and oversight can create space for unsafe alternatives.
Addressing this challenge requires more than enforcement. It calls for stronger systems, better coordination, and informed consumer choices. Ensuring the safety of medicines is not just a regulatory priority but a fundamental requirement for public health trust.
Also Read: Inside India’s Food Safety Raids: From Mango Pulp To Ghee, Adulteration Scandal Unfolds
